Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2024-01-02 00:00:00 ET · period of report 2023-12-29 · accession 0001415889-24-000070 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-01-02 | 2023-12-29 | OLMA | Harmon Cyrus | Dir | S - Sale | $13.38 | -25.0K | 903.8K | -3% | -$334.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-29 | S | D | 2,500 | $14.10 | 901,283 | D | — | — | (F3) The weighted average sale price for the transaction reported was $14.10, and the range of prices was between $14.08 and $14.27. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2023-12-29 | S | D | 22,500 | $13.30 | 903,783 | D | — | — | (F2) The weighted average sale price for the transaction reported was $13.30, and the range of prices was between $13.15 and $13.87. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |